[HTML][HTML] Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies

K Dhama, F Nainu, A Frediansyah, MI Yatoo… - Journal of infection and …, 2023 - Elsevier
Newly emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
are continuously posing high global public health concerns and panic resulting in waves of …

Recent developments in the immunopathology of COVID‐19

H Zhang, Y Sun, Y Wang, D Yazici, D Azkur, I Ogulur… - Allergy, 2023 - Wiley Online Library
There has been an important change in the clinical characteristics and immune profile of
Coronavirus disease 2019 (COVID‐19) patients during the pandemic thanks to the …

[HTML][HTML] Omicron (B. 1.1. 529) variant of SARS‐CoV‐2: concerns, challenges, and recent updates

RK Mohapatra, R Tiwari, AK Sarangi… - Journal of medical …, 2022 - ncbi.nlm.nih.gov
Omicron (B.1.1.529) variant of SARS‐CoV‐2: Concerns, challenges, and recent updates -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …

[HTML][HTML] Clinical characteristics of COVID-19 patients infected by the Omicron variant of SARS-CoV-2

J Zhang, N Chen, D Zhao, J Zhang, Z Hu… - Frontiers in medicine, 2022 - frontiersin.org
Background Currently, as the omicron variant of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) surges amid the coronavirus disease 2019 (COVID-19) …

Sensitivity to vaccines, therapeutic antibodies, and viral entry inhibitors and advances to counter the SARS-CoV-2 Omicron variant

H Zhou, M Møhlenberg, JC Thakor… - Clinical microbiology …, 2022 - Am Soc Microbiol
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) keeps evolving and
mutating into newer variants over time, which gain higher transmissibility, disease severity …

An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS‐CoV‐2

L Zhang, KK Narayanan, L Cooper… - EMBO Molecular …, 2022 - embopress.org
Monoclonal antibodies targeting the SARS‐CoV‐2 spike (S) neutralize infection and are
efficacious for the treatment of COVID‐19. However, SARS‐CoV‐2 variants, notably …

[HTML][HTML] Molnupiravir: A versatile prodrug against SARS-CoV-2 variants

D Teli, P Balar, K Patel, A Sharma, V Chavda, L Vora - Metabolites, 2023 - mdpi.com
The nucleoside analog β-DN 4-hydroxycytidine is the active metabolite of the prodrug
molnupiravir and is accepted as an efficient drug against COVID-19. Molnupiravir targets the …

[HTML][HTML] Infection of lung megakaryocytes and platelets by SARS-CoV-2 anticipate fatal COVID-19

A Zhu, F Real, C Capron, AR Rosenberg… - Cellular and Molecular …, 2022 - Springer
Abstract SARS-CoV-2, although not being a circulatory virus, spread from the respiratory
tract resulting in multiorgan failures and thrombotic complications, the hallmarks of fatal …

MiRNA-SARS-CoV-2 dialogue and prospective anti-COVID-19 therapies

M Panda, E Kalita, S Singh, K Kumar, A Rao… - Life Sciences, 2022 - Elsevier
COVID-19 is a highly transmissible disease caused by severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2), affects 226 countries and continents, and has resulted in> 6.2 …

[HTML][HTML] The regulation of lncRNAs and miRNAs in SARS-CoV-2 infection

Y Lin, Q Sun, B Zhang, W Zhao, C Shen - Frontiers in Cell and …, 2023 - frontiersin.org
The coronavirus disease 2019 (COVID-19) was a global endemic that continues to cause a
large number of severe illnesses and fatalities. There is increasing evidence that non-coding …